Ariana Pelosci

Results from the INTERpath-001 trial of V0940 plus pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in resected melanoma.

Based on 2.5-year OS data from a phase 2b trial, the FDA has granted a Type C meeting to discuss OST-HER2 in fully resected, pulmonary metastatic osteosarcoma.

Data from the phase 3 EXCALIBER-RRMM trial support the FDA accelerated approval of iberdomide plus daratumumab and hyaluronidase and dexamethasone in this multiple myeloma population.

The primary end point of PFS-6 was met in the phase 2 NEO100-01 trial assessing NEO100 in patients with grade III/IV IDH1-mutant glioma.

A multidisciplinary panel broke down ILC's distinct biology, imaging challenges, and emerging trial data, including OFSET and SUMMIT.

Ramy Sedhom, MD, blind-ranks landmark geriatric oncology and palliative care trials, picks his oncology Hall of Fame, and shares career advice on this episode of Double Blind.

Data from the PSMAddition trial support the approval of the radioligand-based regimen for this prostate cancer population.

Kay Yoon-Flannery, DO, MPH, FACS, discusses da Vinci Single Port robotic mastectomy, ranging from technique and patient selection to outcomes.

The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.

A breast surgeon and a radiologist describe the impact the breast biopsy needle shortage has had on their current clinical practice.

Miguel A. Materin, MD, discussed his new leadership role at Northwell Cancer Institute, and why a multidisciplinary approach is critical to managing ocular malignancies.

Nicholas Hornstein, MD, PhD, ranks RASolute 302, BREAKWATER, MATTERHORN, and more in a real-time discussion on Double Blind.

The FDA has accepted a BLA resubmission for RP1 plus nivolumab for patients with advanced melanoma.

Results from the phase 3 ASCENT-03 and ASCENT-04 trials supported the FDA approval across both locally advanced or metastatic TNBC indications.

Findings from the phase 3 PATINA trial support the FDA approval of palbociclib plus trastuzumab with or without pertuzumab in this breast cancer population.

Experts discussed the integration of GLP-1 agonists and lifestyle interventions to mitigate obesity-related cancer risks and improve long-term survival.

Based on data from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan/pembrolizumab for patients with clear cell RCC.

Catch up on major clinical trials reshaping treatment for brain metastases, Merkel cell carcinoma, cervical cancer, and head and neck cancer, all from ASCO 2026.

Patients with breast cancer experienced improvement in vasomotor symptoms when treated with elinzanetant, irrespective of type of endocrine therapy.

Results from cohort C of the TRASTS study showed trabectedin/radiotherapy had positive response rates for patients with resectable retroperitoneal L-sarcomas.

For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis.

In 897 patients with advanced melanoma treated with ICI, conditional 5-year PFS rose from 29% at baseline to 91% for those progression-free at 4 years.

Sacituzumab govitecan plus pembrolizumab maintained PFS improvements vs chemotherapy plus pembrolizumab in first-line metastatic TNBC.

An OS of 32.9 months was noted with RP1 plus nivolumab for patients who had progressed on prior anti-PD-1 therapy with advanced melanoma.

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

Patients with breast cancer who omitted sentinel lymph node surgery did not have an increased uptake in other forms of treatment like radiation therapy.

Data from the phase 3 VERITAC-2 trial support the FDA approval of vepdegestrant in this breast cancer population.

Post-surgical treatment, functional gains were improved among patients with breast cancer.

iSCIB1+ continues to be studied in the SCOPE trial for patients with advanced melanoma.

The 5-year OS rate was 16% and 8% in the tebentafusp and control arms, respectively, for patients with HLA-A*02:01–positive uveal melanoma.